Actively Recruiting
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
Led by University of Chicago · Updated on 2025-10-07
21
Participants Needed
1
Research Sites
37 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To assess if PD-L1 expression can be upregulated in peritoneal metastases from gastric cancer after the administration of HIPEC with greater frequency compared to systemic chemotherapy alone
CONDITIONS
Official Title
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with confirmed gastric cancer with peritoneal metastases and/or positive peritoneal cytology who have completed systemic chemotherapy for 2 to 4 months
- Age 18 years or older
- ECOG performance status of 2 or better (Karnofsky 60% or higher)
- Adequate organ and marrow function including leukocytes ≥3,000/mcL, absolute neutrophil count ≥1,500/mcL, platelets ≥100,000/mcL, total bilirubin within normal limits, AST/ALT ≤3 times normal, creatinine within normal limits or GFR ≥50 mL/min/1.73 m²
- HIV-infected patients on effective therapy with undetectable viral load within 6 months
- Patients with controlled hepatitis B or cured hepatitis C infection
- Patients with prior or concurrent malignancies that do not interfere with study assessments
- Cardiac function class 2B or better by New York Heart Association criteria
- Expected survival greater than 3 months
- Women of child-bearing potential and men must agree to use effective contraception during and after the study
- Ability to understand and sign informed consent
You will not qualify if you...
- Presence of another untreated cancer (except basal cell skin cancer) within the last 5 years
- Metastases beyond loco-regional lymph nodes and peritoneum (e.g., liver, lungs, bone, brain)
- Unresolved toxicities greater than Grade 1 from prior anti-cancer therapy, except alopecia
- Use of other investigational agents
- Allergic reactions to cisplatin or Mitomycin C or similar compounds
- Uncontrolled illness
- Psychiatric or social conditions limiting study compliance
- Pregnant or breastfeeding women due to potential risks of cisplatin and Mitomycin C
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Chicago
Chicago, Illinois, United States, 60637
Actively Recruiting
Research Team
C
Cancer Clinical Trials Office
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here